Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study

M. Gattorno, L. Obici, M. Cattalini, V. Tormey, K. Abrams, N. Davis, A. Speziale, S. G. Bhansali, A. Martini, H. J. Lachmann

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To evaluate the efficacy of canakinumab, a high-affinity human monoclonal anti-interleukin-1beta antibody, in inducing complete or almost complete responses in patients with active tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Twenty patients (aged 7-78 years) with active recurrent or chronic TRAPS were treated with canakinumab 150 mg every 4 weeks for 4 months (2 mg/kg for those
Original languageEnglish
Pages (from-to)173-178
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume76
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Keywords

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal/administration & dosage/adverse effects/blood/therapeutic use
  • Child
  • Chronic Disease
  • Drug Administration Schedule
  • Familial Mediterranean Fever/drug therapy/genetics
  • Female
  • Humans
  • Immunologic Factors/administration & dosage/blood/therapeutic use
  • Male
  • Middle Aged
  • Quality of Life
  • Receptors, Tumor Necrosis Factor/genetics
  • Recurrence
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult
  • Cytokines
  • Fever Syndromes
  • TNF-alpha
  • Treatment

Fingerprint Dive into the research topics of 'Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study'. Together they form a unique fingerprint.

  • Cite this